Durvalumab
Bevacizumab-alone Maintenance Treatment Progression
Centro Nacional de Investigaciones Oncologicas CARLOS IIImonoclonal_antibodyEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Bevacizumab-alone Maintenance Treatment Progression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Centro Nacional de Investigaciones Oncologicas CARLOS III | Early Phase 1 | CC |
(+)-VINCRISTINE Centro Nacional de Investigaciones Oncologicas CARLOS III | Early Phase 1 | CC |
Same molecule, other indications
Durvalumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →